1. Home
  2. ADVM vs TGE Comparison

ADVM vs TGE Comparison

Compare ADVM & TGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • TGE
  • Stock Information
  • Founded
  • ADVM 2006
  • TGE 2023
  • Country
  • ADVM United States
  • TGE France
  • Employees
  • ADVM N/A
  • TGE N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • TGE Newspapers/Magazines
  • Sector
  • ADVM Health Care
  • TGE Consumer Discretionary
  • Exchange
  • ADVM Nasdaq
  • TGE Nasdaq
  • Market Cap
  • ADVM 94.6M
  • TGE 85.8M
  • IPO Year
  • ADVM 2014
  • TGE N/A
  • Fundamental
  • Price
  • ADVM $4.32
  • TGE $1.27
  • Analyst Decision
  • ADVM Buy
  • TGE
  • Analyst Count
  • ADVM 5
  • TGE 0
  • Target Price
  • ADVM $16.60
  • TGE N/A
  • AVG Volume (30 Days)
  • ADVM 1.0M
  • TGE 11.8M
  • Earning Date
  • ADVM 11-07-2025
  • TGE 10-20-2025
  • Dividend Yield
  • ADVM N/A
  • TGE N/A
  • EPS Growth
  • ADVM N/A
  • TGE N/A
  • EPS
  • ADVM N/A
  • TGE N/A
  • Revenue
  • ADVM $1,000,000.00
  • TGE $130,212,000.00
  • Revenue This Year
  • ADVM $1,449.40
  • TGE N/A
  • Revenue Next Year
  • ADVM N/A
  • TGE N/A
  • P/E Ratio
  • ADVM N/A
  • TGE $3.10
  • Revenue Growth
  • ADVM N/A
  • TGE 81.03
  • 52 Week Low
  • ADVM $1.78
  • TGE $0.78
  • 52 Week High
  • ADVM $8.18
  • TGE $37.02
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 50.91
  • TGE N/A
  • Support Level
  • ADVM $4.18
  • TGE N/A
  • Resistance Level
  • ADVM $4.34
  • TGE N/A
  • Average True Range (ATR)
  • ADVM 0.26
  • TGE 0.00
  • MACD
  • ADVM -0.05
  • TGE 0.00
  • Stochastic Oscillator
  • ADVM 40.96
  • TGE 0.00

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

Share on Social Networks: